March 13, 2009-HI-Eisai Pharmaceutical Inc., a subsidiary in the Philippines of Eisai Co., Ltd. announced today that the Bureau of Food and Drugs (BFAD) approved “Clevudine” for the inhibition of virus replication in chronic hepatitis B patients (HbeAg positive or HbeAg negative) with evidence of active viral replication and elevations in serum aminotransferases (ALT or AST).
The details can be read here.
No comments:
Post a Comment